33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II multicenter clinical trial assessing the safety and efficacy of ixazomib, pomalidomide and dexamethasone combination as second or third-line treatment for triple-class exposed patients with relapsed and refractory multiple myeloma (iPod-790 Trial)
    Meeting Abstract

    Cohen, Y. C.; Shragai, T.; Lavi, N.; Vaxman, I.; Chubar, E.; Gatt, M. E.; Ganzel, C.; Magen, H.; Luttwak, E.; Mittelman, M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Comparative effectiveness of axicabtagene ciloleucel vs historical standard-of-care in patients with relapsed or refractory follicular lymphoma: An analysis of CIBMTR and SCHOLAR-5 data
    Meeting Abstract

    Kambhampati, S.; Wang, H. L.; Yan, J.; Herrera, A. F.; Frank, M. J.; Popplewell, L. L.; Ahmed, N.; Lin, Y.; Locke, F. L.; Ghione, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • HMGA1 chromatin regulators drive immune evasion in MPN progression through epigenetic rewiring to repress antigen presentation
    Meeting Abstract

    Kim, J.; Supreme, A. A.; West, B.; Antopia, M. C.; Reddy, K.; Cope, L.; Kim, J. H.; Rampal, R. K.; Koche, R.; Spivak, J. L.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Novel causal inference method estimates treatment effects of contemporary drugs in a global cohort of patients with relapsed and refractory mature T-cell and NK-cell neoplasms
    Meeting Abstract

    Koh, M. J.; Boussi, L.; Han, J. X.; Peng, L.; Sorial, M. N.; Eche-Ugwu, I. J.; Miranda, E.; Chiattone, C.; Stuver, R.; Horwitz, S. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Glofitamab (Glofit) plus R-CHOP has a favorable safety profile and induces high response rates in patients with previously untreated (1L) large B-cell lymphoma (LBCL) defined as high risk by circulating tumor DNA (ctDNA) dynamics: Preliminary safety and efficacy results
    Meeting Abstract

    Falchi, L.; Jardin, F.; Haioun, C.; Wrobel, T.; Mészáros Joergensen, J.; Bastos-Oreiro, M.; Mou, E.; Martinez-Lopez, J.; Budde, L. E.; Bartlett, N. L.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Updated findings of a phase II study of ruxolitinib pre-, during- and post-hematopoietic stem cell transplantation for patients with primary or secondary myelofibrosis
    Meeting Abstract

    Hobbs, G. S.; Kim, H. T.; O'Connor, S.; Schroeder, M. A.; Tamari, R.; Wall, S. A.; El-Jawahri, A.; McAfee, S.; Hem, J.; Lozano, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A personalized whole genome-informed assay targeting single mutant in circulating tumor DNA can identify MRD and predict relapse in DLBCL
    Meeting Abstract

    Merryman, R. W.; Rhoades, J.; Xiong, K.; Antel, K.; An, H. H.; Redd, R. A.; McDonough, M. M.; Guerrero, L.; Crnjac, A.; Sridhar, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Effects of idecabtagene vicleucel (ide-cel) versus standard regimens on health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM) who had received 2-4 prior regimens: Updated results from the phase 3 KarMMa-3 trial
    Meeting Abstract

    Delforge, M.; Patel, K. K.; Eliason, L.; Dhanda, D.; Shi, L.; Guo, S.; Marshall, T. S.; Arnulf, B.; Cavo, M.; Nooka, A. K.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Early results indicate acceptable safety and promising efficacy of venetoclax in combination with pola-R-CHP for untreated high-risk BCL-2-positive B-cell lymphoma including double/triple hit lymphoma
    Meeting Abstract

    Zelenetz, A. D.; Diefenbach, C. S.; Herbaux, C.; Tani, M.; Houot, R.; Bastos-Oreiro, M.; Tilly, H.; Gastinne, T.; Thieblemont, C.; Troy-Barnes, E.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • I-DATA Study: Randomized, sequential, open-label study to evaluate the efficacy of IDH targeted/non- targeted versus non-targeted/IDH-targeted approaches in the treatment of newly diagnosed IDH mutated adult AML patients not candidates for intensive induction therapy
    Meeting Abstract

    Ozga, M. P.; Dvorak-Kornaus, K. M.; Zhao, Q.; Buss, J.; Laganson, A.; Hamp, E.; Madanat, Y. F.; Pollyea, D. A.; Stein, E. M.; Zeidner, J. F.; more...
    Blood (2023)

    Fulltext@MSK | Save